Press releases worldwide
Lonza to acquire and operate Codiak’s Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline Lonza and Codiak to establish a Center of Excellence focused on exosome manufacturing and characterization technologies Lonza to gain access to […]
At its Capital Markets Day, Lonza outlined strategic priorities and innovation highlights with a clear focus on sustainable value creation Accelerated, de-risked, long-term investment program will drive sustainable business growth 2021 CAPEX anticipated at around 25% of sales, and remain […]
. Lonza will invest to expand its drug product manufacturing network in Switzerland The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel (CH) The expansion […]
. Triumvira’s T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza’s Cocoon® platform at the C3i Center Inc (C3i) in Montreal Transitioning to Lonza’s Cocoon® Platform enabled Triumvira to escalate development efforts and achieve IND approval in […]
Lonza appoints Philippe Deecke as CFO and member of the Lonza Group Executive Committee Philippe brings a wealth of experience from a 30-year career, which includes senior leadership roles in Novartis finance and time working as a McKinsey consultant […]
In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaborations to support COVID-19 programs including […]
. Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal enables the customer to access commercial-scale production of all elements […]
. Lonza announced today the completion of the divestment of its former Specialty Ingredients business and operations to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion. Albert M. Baehny, Chairman, Lonza commented: “Since announcing our intention […]
Lonza reports restated 2020 financials for sales, EBIT, EBITDA and CORE EBITDA Lonza now provides 2020 financials in the redesigned business structure to reflect divisional performance Prior to the reporting of the Half-Year Results 2021 on 23 July 2021, Lonza […]
47,080,080 shareholders delegated their votes to the independent proxy, representing 63.22% of the share capital Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors for another year A […]